Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.
Hughes TP, Branford S, White DL, Reynolds J, Koelmeyer R, Seymour JF, Taylor K, Arthur C, Schwarer A, Morton J, Cooney J, Leahy MF, Rowlings P, Catalano J, Hertzberg M, Filshie R, Mills AK, Fay K, Durrant S, Januszewicz H, Joske D, Underhill C, Dunkley S, Lynch K, Grigg A; Australasian Leukaemia and Lymphoma Group. Hughes TP, et al. Among authors: durrant s. Blood. 2008 Nov 15;112(10):3965-73. doi: 10.1182/blood-2008-06-161737. Epub 2008 Sep 3. Blood. 2008. PMID: 18768781 Free article. Clinical Trial.
Safe mobilization of normal progenitors in advanced chronic myeloid leukemia with intensive chemotherapy and granulocyte-colony stimulating factor.
Morton J, Mollee P, Taylor K, Grigg A, Durrant S, Moore D, Rodwell R, Eliadis P, Hutchins C, Williams B, Seeley G, Wright S, Kelly C, Rentoul A, Iland H, Atkinson K, Januszewicz H, Bunce I, Bashford J, Stewart C, Taylor D. Morton J, et al. Among authors: durrant s. Leuk Res. 1999 Feb;23(2):177-83. doi: 10.1016/s0145-2126(98)00143-x. Leuk Res. 1999. PMID: 10071133
Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia.
Bradstock K, Matthews J, Young G, Lowenthal R, Baxter H, Arthur C, Bashford J, Brighton T, Cannell P, Dunlop L, Durrant S, Enno A, Eliadis P, Gill D, Gillett A, Gottlieb D, Januszewicz H, Joshua D, Leahy M, Schwarer A, Taylor K; Australian Leukaemia Study Group. Bradstock K, et al. Among authors: durrant s. Leukemia. 2001 Sep;15(9):1331-8. doi: 10.1038/sj.leu.2402218. Leukemia. 2001. PMID: 11516093 Clinical Trial.
Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Branford S, Rudzki Z, Harper A, Grigg A, Taylor K, Durrant S, Arthur C, Browett P, Schwarer AP, Ma D, Seymour JF, Bradstock K, Joske D, Lynch K, Gathmann I, Hughes TP. Branford S, et al. Among authors: durrant s. Leukemia. 2003 Dec;17(12):2401-9. doi: 10.1038/sj.leu.2403158. Leukemia. 2003. PMID: 14523461 Clinical Trial.
209 results